To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have evidence of a return of multiple myeloma after autologous stem cell transplantation and receipt of lenalidomide maintenance therapy.
- Patients may not yet have symptoms of multiple myeloma or organ damage.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Hani Hassoun at 212-639-3228.